Comparative Pharmacology
Head-to-head clinical analysis: LUVOX CR versus PEXEVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUVOX CR versus PEXEVA.
LUVOX CR vs PEXEVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
100-300 mg orally once daily at bedtime
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
None Documented
None Documented
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant